

Contents

Preface to the Third Edition xiii
List of Figures xv
List of Tables xix
List of Contributors xxiii

I

MECHANISMS OF LIVER INJURY

1. Drug-Induced Liver Injury

NEIL KAPLOWITZ

Introduction 3
Clinical Overview 3
Pathogenesis 6
Diagnosis 9
Drug Development 10
Postmarketing Monitoring 11
Conclusions 12
References 13

2. Cytochrome P450 Activation of Toxins and Hepatotoxicity 15

F PETER GUENGERICH

Introduction 15
Cytochrome P450 Enzymes 16
Contexts of Toxicity 19
Bioactivation Reactions 22
Strategies for Screening in Drug Development 26
The Issue of Human-Specific Metabolites 29
Conclusions 29
References 30

3. Mechanistic Role of Acyl Glucuronides 35

HOWARD HORNG, HILDE SPAHN-LANGGUTH, AND LESLIE Z. BENET

Introduction 35
Overview of Major Types of Chemical Reactivities of Acyl Glucuronides 36
Biochemical Aspects of Acyl Glucuronidation 38
Synthesis, Isolation, and Characterization of Acyl Glucuronides 39
Stability of Acyl Glucuronides 44
Reversible Binding of Acyl Glucuronides to Proteins 48
Covalent Binding of Acyl Glucuronides to Proteins 48
Stereochemical Aspects of Acyl Glucuronides 57
Predictability of the Covalent Binding of Acidic Drugs 59

In Vitro Reactivity Screens Utilizing Nucleophilic Trapping Agents 61
Potential Toxicological Significance of the Reactive Acyl Glucuronides 62
Acknowledgments 64
References 64

4. Oxidant Stress, Antioxidant Defense, and Liver Injury 71

MITCHELL R. MCGILL AND HARTMUT JAESCHKE

Introduction 71
The Major Reactive Oxygen and Nitrogen Species in the Liver and Their Sources 72
Pathophysiological Consequences of Oxidative Stress 74
Antioxidants 76
Drug-Induced Oxidative Stress in the Liver 80
References 80

5. Hepatotoxicity Due to Mitochondrial Injury 85

JOHN J. LEMASTERS

Introduction 85
Overview of Mitochondria 85
Mitochondrial Permeability Transition 88
Mitochondria and Drug-Induced Hepatic Steatosis 93
Conclusions 95
Acknowledgments 95
References 95

6. Mechanisms of Cell Death and Relevance to Drug Toxicity 101

LILY DARA, DERICK HAN, AND NEIL KAPLOWITZ

Introduction 101
Classification of Cell Death 102
Apoptosis 103
Autophagy 106
Necrosis: A Programmed Process? 108
Cell Death in DILI 110
Conclusions 116
References 116

7. Role of Membrane Transport in Hepatotoxicity and Pathogenesis of Drug-Induced Cholestasis 123

BRUNO STIEGER AND GERD A. KULLAK-UBLICK

Introduction 123
Bile Formation 123
Clinical Features of Drug-Induced Cholestasis 124

Hepatocellular Drug Uptake and Intracellular Drug Concentrations	125
Mechanisms of BSEP Inhibition	125
Impact of Elevated Intracellular Bile Salt Levels on Transporter Expression	126
Susceptibility Factors for Drug-Induced Cholestasis	128
Conclusions	129
References	129

8. Liver Sinusoidal Endothelial Cells and Liver Injury 135

Laurie D. Deleve

Introduction	135
Liver Sinusoidal Endothelial Cells	136
Capillarization, Pseudocapillarization, and Drug Metabolism	137
Liver Sinusoidal Endothelial Cells and Fibrosis	137
Bone Marrow Liver Sinusoidal Endothelial Progenitor Cells and Liver Regeneration	138
Manifestations of Liver Sinusoidal Endothelial Cell Injury	138
Lesions of Heterogeneous Perfusion	138
Peliosis Hepatis	139
Sinusoidal Obstruction Syndrome	140
Acetaminophen	142
Gemtuzumab Ozogamicin	142
Oxaliplatin	143
Conclusions	143
References	143

9. Macrophages and Kupffer Cells in Drug-Induced Liver Injury 147

Mark Barnes, Laura J. Dixon, Zhang-Xu Liu, Hui Tang, and Laura E. Nagy

Introduction	147
Innate Immune Activation in DILI	148
Interactions Between Hepatic Macrophages and Other Cells in the Liver During DILI	150
Danger Signals Generated in Drug-Induced Liver Injury and Their Signaling Pathways	150
Additional DAMPs/PAMPs Involved in Macrophage Activation in DILI	151
Complement and Macrophage Activation	151
Diagnosis and Treatment of Drug-Induced Liver Injury: Can Macrophages Be a Target?	152
Genetic Susceptibility to DILI	152
Conclusions	153
References	153

10. Role of Inflammation in Drug-Induced Liver Injury 157

Robert A. Roth and Patricia E. Ganey

Introduction	157
Inflammation as a Progression Factor in Idiosyncratic DILI	159
Inflammation in Idiosyncratic DILI Responses	165
Exogenously Imposed Inflammation as a Susceptibility Factor for Drug-Induced Liver Injury	166

Conclusions	169
Acknowledgments	169
References	169

11. Role of the Adaptive Immune System in Idiosyncratic Drug-Induced Liver Injury 175

Jack Uetrecht

Introduction	175
Clinical Characteristics of IDRS	176
Evidence Suggesting that IDILI is Immune Mediated	177
Alternative Hypotheses	180
Toward a Unifying Hypothesis for IDILI	182
Conclusions	189
Acknowledgments	189
References	189

12. Role of Tissue Repair and Death Proteins in Liver Injury 195

Harihara M. Mehendale

Introduction	195
Two-Stage Model of Toxicity	196
Tissue Repair Follows a Dose Response	197
Dose-Responsive Tissue Repair for Mixtures of Hepatotoxicants	198
Tissue Repair as a Determinant of the Final Outcome of Toxicity	198
Relationship Between Higher Initiation of Liver Injury and Tissue Repair	200
Factors Affecting Tissue Repair	201
Progression of Liver Injury	204
Regression of Injury	207
Significance of Tissue Repair	209
Significance of Death Proteins in the Spread of Liver Injury	209
Conclusions	209
References	210

13. Genetic Factors in the Pathogenesis of Drug-Induced Liver Injury 215

Ann K. Daly and Christopher P. Day

Introduction	215
Methods and Approaches Used to Identify Genetic Factors in DILI	216
Genetic Factors Predicting DILI Susceptibility	216
Conclusions	222
References	222

II

DIAGNOSIS AND MANAGEMENT

14. Clinical Manifestations and Management of Drug-Induced Liver Diseases 229

Willis C. Maddrey

Introduction	229
Susceptibility Factors: Drug-Induced Liver Injury	230

Clinical Recognition of a Suspected or Probable DILI	231
Clinical and Laboratory Manifestations	231
Manifestations of DILI	232
Nonspecificity of Clinical and Laboratory Manifestations of DILD	232
Signals of Severe Drug-Induced Liver Injury: The Importance of Hy's Law	233
The Important Issue of Drug-Induced Autoimmune Hepatitis	234
Drugs of Special Interest	234
Management and Treatment of DILD	238
Rechallenge	238
References	238

15. Histopathological Evaluation of Drug-Induced Liver Disease 241

DAVID E. KLEINER

Introduction	241
Role of Pathological Evaluation in DILD	242
Patterns of Injury in DILD	242
Using Liver Biopsy to Evaluate DILD	258
Conclusions	260
Acknowledgments	261
References	261

16. Risk Factors for Drug-Induced Liver Disease 265

RAJ VUPPALANCHI AND NAGA CHALASANI

Introduction	265
Host-Related Risk Factors	266
Environmental Risk Factors	269
Compound-Related Risk Factors	269
Conclusions	271
Acknowledgments	271
References	272

17. Biomarkers for Drug-Induced Liver Injury 275

PAUL B. WATKINS

Introduction	275
Current Status of Hepatocellular DILI Biomarkers	276
The Road to Better DILI Biomarkers	277
Metabolomics	278
Transcriptomics	279
Proteomics	280
Example of an Application of Novel Biomarkers to a Clinical Trial: Heparins	282
Serum Protein Adducts	282
Anti-Liver Antibodies	283
Lymphocyte Transformation Test	283
Conclusions	283
References	283

18. Causality Assessment 287

M. ISABEL LUCENA, CAMILLA STEPHENS, MIREN GARCÍA-CORTÉS,
AND RAÚL J. ANDRADE

Introduction	287
Diagnosis in the Clinical Setting	288
Minimal Elements for Drug-Induced Liver Injury Diagnosis and Publishing	294
Causality Assessment	295
Conclusions	299
References	301

III

HEPATOTOXICITY OF SPECIFIC DRUGS

19. Mechanisms of Acetaminophen-Induced Liver Disease 305

JACK A. HINSON

Introduction	305
Reactive Metabolite Formation	306
Protein Covalent Binding	307
Toxicity Occurs in Two Phases	310
Alterations in Calcium Metabolism	310
Oxidative Stress and Toxicity	311
Mitochondrial Permeability Transition	313
Antioxidant Defense Mechanisms	315
Cell Signaling and Mitochondrial Permeability Transition	317
Hepatic Inflammation	318
Genomics, Proteomics, and Metabolomics	321
Conclusions	321
Acknowledgments	322
References	322

20. Acetaminophen 331

LAURA P. JAMES

Introduction	331
Pharmacology of Acetaminophen	332
Availability of Acetaminophen and Considerations on Regulation	332
Clinical Presentation of Acetaminophen Toxicity	333
Definitions of Toxicity	334
Biomarkers of Toxicity	335
Patient Variability and Acetaminophen Toxicity	335
Acknowledgments	338
References	339

21. Mechanisms Underlying the Hepatotoxicity of Nonsteroidal Antiinflammatory Drugs 343

URS A. BOELSTERLI

- NSAID Hepatotoxicity: A Paradigm of IDILI 344
 Toxicokinetic Determinants of NSAID Hepatotoxicity:
 Disposition and Metabolism 345
 Toxicodynamic Determinants of NSAID Hepatotoxicity: Cellular
 and Molecular Mechanisms 351
 Patient-Specific Determinants of Susceptibility to NSAID
 Hepatotoxicity 359
 Conclusions 360
 References 361

22. Nonsteroidal Antiinflammatory Drugs and Leukotriene Receptor Antagonists 369

JAMES H. LEWIS AND JONATHAN G. STINE

- Introduction 370
 Incidence of NSAID-Induced Hepatic Injury 370
 Effect of Rheumatic Diseases on the Liver 372
 Clinical and Biochemical Spectrum of NSAID-Induced Hepatic
 Injury 372
 Hepatic Injury Due to Individual NSAIDs 377
 Hepatic Injury Due to DMARDs 388
 Hepatotoxicity of Leukotriene Receptor Antagonists 389
 Hepatotoxicity of Agents Used in the Treatment of Gout 390
 Monitoring for NSAID and Other Antiinflammatory
 Drug-Induced Hepatic Injury 391
 References 393

23. Mechanism, Pathology, and Clinical Presentation of Hepatotoxicity of Anesthetic Agents 403

J. GERALD KENNA

- Introduction 403
 Clinical Features of Volatile Anesthetic-Induced
 Hepatotoxicity 404
 Metabolism of Volatile Anesthetics 406
 Adaptive Immune Responses in Patients with Anesthetic-Induced
 Liver Injury 408
 Animal Models 412
 Hydrochlorofluorocarbon Refrigerants 415
 Mechanism of Volatile Anesthetic-Induced Liver Injury and Basis
 of Individual Susceptibility 415
 Conclusions 417
 References 417

24. Anticonvulsant Agents 423

MUNIR PIRMOHAMED AND J. STEVEN LEEDER

- Introduction 423
 Carbamazepine 424
 Oxcarbazepine 427
 Phenytoin 428
 Phenobarbital 430
 Valproic Acid 430
 Felbamate 435

- Lamotrigine 435
 Management 436
 References 437

25. Hepatotoxicity of Psychotropic Drugs and Drugs of Abuse 443

DOMINIQUE LARREY AND MARIE-PIERRE RIPAUT

- Introduction 444
 Epidemiological Aspects of Psychotropic Hepatotoxicity 444
 Identification of Drug-Induced Liver Injury Caused by
 Psychotropic Agents 445
 Factors that Contribute to the Hepatotoxicity of Psychotropic
 Agents 446
 Antidepressants 447
 Neuroleptic Agents 452
 Anxiolytic Agents 455
 Psychostimulating Agents 455
 Thymoregulating Agents 455
 Herbal Medicines 455
 Illegal and Recreational Compounds 456
 Conclusions 457
 References 457

26. Hepatotoxicity of Antimicrobials and Antifungal Agents 463

RICHARD H. MOSELEY

- Introduction 463
 Antibacterial Agents 464
 Antifungal Agents 470
 Conclusions 473
 References 473

27. Hepatotoxicity of Antitubercular Drugs 483

SUMITA VERMA AND NEIL KAPLOWITZ

- Introduction 483
 Incidence of Hepatotoxicity 485
 Mechanism of Hepatotoxicity 486
 Hepatotoxicity of Individual Drugs 488
 Hepatotoxicity with Multidrug Antitubercular Therapy 489
 Risk Factors for Antitubercular Therapy Hepatotoxicity 490
 Clinical, Biochemical, and Histological Features 494
 Management, Including Referral for Liver Transplant 495
 Alternative Therapy for Underlying Tuberculosis and
 Reintroduction of Antitubercular Therapy 496
 Antitubercular Therapy in Patients with Underlying Liver
 Disease 497
 Hepatotoxicity of Antitubercular Therapy in Liver Transplant
 Recipients 497
 Recommendations for Monitoring Patients While on ATT 498
 Conclusions 499
 References 500

28. Hepatotoxicity of Antiviral Agents 505

MARINA NÚÑEZ

- Introduction 505
 Antiretroviral Drugs 506

- Incidence and Risk Factors for HAART-Related DILI: The Drug and the Host 506
 Clinical Presentations of HAART-Related DILI and Their Mechanisms 508
 Hepatitis Treatments 511
 Herpesviridae Treatment 512
 Influenza Virus Treatments 513
 References 513
- 29. Hepatotoxicity of Cardiovascular and Antidiabetic Drugs 519**
 DINA HALEGOUA-DE MARZIO AND VICTOR J. NAVARRO
- Introduction 519
 Cardiovascular Drugs 520
 Antidiabetic Drugs 528
 Other Agents 531
 Conclusions 532
 References 532
- 30. Cancer Chemotherapy 541**
 LAURIE D. DELEVE
- Introduction 541
 Hepatic Metabolism of Anticancer Drugs 542
 Liver Toxicity and Hematopoietic Stem Cell Transplantation 548
 Hepatotoxicity by Anticancer Therapy 550
 Selected Anticancer Drugs and Modalities 551
 Conclusions 559
 References 559
- 31. Hepatotoxicity of Immunosuppressive Drugs 569**
 ADRIAN REUBEN
- Classification of Immunosuppressive Agents 569
 Hepatotoxicity of Immunosuppressives in Current Clinical Practice 570
 Conclusions 582
 References 582
- 32. Hepatotoxicity Related to Methotrexate 593**
 GURUPRASAD P. AITHAL
- Introduction 593
 Acute DILI 594
 Methotrexate-Associated Chronic Liver Disease 594
 Pathogenesis of Methotrexate-Associated Chronic Liver Disease 598
 Monitoring for Methotrexate-Associated Chronic Liver Disease 599
 Conclusions 602
 References 602
- 33. Adverse Effects of Hormones and Hormone Antagonists on the Liver 605**
 SHIVAKUMAR CHITTURI AND GEOFFREY C. FARRELL
- Introduction 605
 Oral Contraceptive Steroids 606
- Anabolic Androgenic Steroids 609
 Estrogen Receptor Antagonists 610
 Antiandrogens 612
 Corticosteroids 613
 Antithyroid Drugs 614
 Conclusions 615
 References 615
- 34. Mushroom Poisoning 621**
 FRANÇOIS DURAND AND DOMINIQUE VALLA
- Introduction 621
Amanita: The Mushrooms 621
 The Toxins 622
Amanita Poisoning: Manifestations 623
 Liver Lesions 624
 Prognosis 625
 Management 625
 Conclusions 627
 Acknowledgment 628
 References 628
- 35. Hepatotoxicity of Herbs and Dietary Supplements 631**
 LEONARD SEEFF, FELIX STICKEL, AND VICTOR J. NAVARRO
- Introduction 632
 Epidemiology of and Expenditure on Herbs and Dietary Supplements 632
 Origin and Production of Herbs and Botanicals for Medicinal Purposes 633
 Regulation of Dietary Supplements 634
 The Use of Herbal Products to Treat Liver Disease 636
 Liver Injury Caused by Herbs and Dietary Supplements 639
 Causality Assessment for Hepatotoxicity Due to Herbs and Dietary Supplements 639
 Limitations of Causality Assessment for Hepatotoxicity Due to Herbs and Dietary Supplements 639
 Herbal Products Associated with Liver Injury 640
 Dietary Supplements Associated with Liver Injury 647
 Natural Toxins 648
 Conclusions 650
 References 650
- 36. Occupational and Environmental Hepatotoxicity 659**
 KEITH G. TOLMAN AND ANTHONY S. DALPIAZ
- Introduction 659
 Types of Injuries 660
 Types of Exposures 660
 Susceptibility to Injury 661
 Testing for Occupational Hepatotoxicity 662
 Mechanisms of Injury 663
 Hepatotoxic Chemicals 664
 Halogenated Aromatic Hydrocarbons 664
 Halogenated Aliphatic Hydrocarbons 664
 Chlorinated Ethylenes 667
 N-Substituted Amides 668

Organochlorine Pesticides, Insecticides, and Herbicides 668
 Miscellaneous Hepatotoxins 669
 Hydraulic Fracturing 670
 Conclusions 670
 References 671

37. Chronic Liver Disease from Drugs 677

EINAR S. BJÖRNSSON

Introduction 677
 Autoimmune Hepatitis Triggered by Drugs 677
 Vanishing Bile Duct Syndrome Associated with Drugs 679
 Liver Cirrhosis Associated with Drugs 679
 Incidence of Chronic Liver Test Abnormalities After DILI 680
 Possible Long-Term Consequences of DILI on the Liver 682
 Conclusions 682
 References 682

IV

FUTURE DIRECTIONS

38. Regulatory Perspectives 689

MARK I. AVIGAN

Introduction 689
 Regulatory and Scientific Challenges in the Assessment of
 Drug-Induced Liver Injury Risk 691
 Assessment of DILI Risk in Clinical Trials 693
 Identification and Characterization of DILI Risk in the
 Postmarket: A Life Cycle Approach 697

Evaluation of Postmarketing DILI Cases 697
 Postmarketing DILI Surveillance Tools 700
 Risk Management of DILI 703
 DILI and the FDA's Role in the Safe Use of Drugs and Biological
 Agents 707
 Future Directions Surrounding DILI: Interface between Science
 and Regulation 708
 References 709

39. Drug-Induced Liver Injury Research Networks 713

ROBERT J. FONTANA

Introduction 713
 Prospective Studies of DILI 714
 Prospective DILI Registries 715
 Retrospective Pharmacoepidemiological Studies of DILI 720
 Acknowledgments 721
 References 721

40. LiverTox 725

JAY H. HOOFNAGLE

Introduction 725
 Introductory Sections 726
 Drug Records 730
 Interactive Section 731
 Conclusions 731
 Acknowledgments 732
 References 732

Index 733